Literature DB >> 32412052

Reply to Luppi et al.

John R Wingard1, Johan Maertens2,3, Livio Pagano4,5, Sharon C-A Chen6, Peter G Pappas7, J Peter Donnelly8.   

Abstract

Entities:  

Year:  2020        PMID： 32412052      PMCID： PMC7819513          DOI： 10.1093/cid/ciaa324

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  9 in total

Review 1.  The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective.

Authors:  A B Satterthwaite; O N Witte
Journal:  Immunol Rev       Date:  2000-06       Impact factor: 12.988

2.  Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Authors:  Asher Chanan-Khan; Paula Cramer; Fatih Demirkan; Graeme Fraser; Rodrigo Santucci Silva; Sebastian Grosicki; Aleksander Pristupa; Ann Janssens; Jiri Mayer; Nancy L Bartlett; Marie-Sarah Dilhuydy; Halyna Pylypenko; Javier Loscertales; Abraham Avigdor; Simon Rule; Diego Villa; Olga Samoilova; Panagiots Panagiotidis; Andre Goy; Anthony Mato; Miguel A Pavlovsky; Claes Karlsson; Michelle Mahler; Mariya Salman; Steven Sun; Charles Phelps; Sriram Balasubramanian; Angela Howes; Michael Hallek
Journal:  Lancet Oncol       Date:  2015-12-05       Impact factor: 41.316

3.  Ibrutinib Is a Newly Recognized Host Factor for the Definition of Probable Invasive Pulmonary Mold Disease, Based on Off-target Effects, Unrelated to Its B-cell Immunosuppressant Activity.

Authors:  Mario Luppi; Fabio Forghieri; Leonardo Potenza
Journal:  Clin Infect Dis       Date:  2020-12-15       Impact factor: 9.079

4.  Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.

Authors:  Ariela Noy; Sven de Vos; Catherine Thieblemont; Peter Martin; Christopher R Flowers; Franck Morschhauser; Graham P Collins; Shuo Ma; Morton Coleman; Shachar Peles; Stephen Smith; Jacqueline C Barrientos; Alina Smith; Brian Munneke; Isaiah Dimery; Darrin M Beaupre; Robert Chen
Journal:  Blood       Date:  2017-02-06       Impact factor: 22.113

5.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Authors:  Jan A Burger; Alessandra Tedeschi; Paul M Barr; Tadeusz Robak; Carolyn Owen; Paolo Ghia; Osnat Bairey; Peter Hillmen; Nancy L Bartlett; Jianyong Li; David Simpson; Sebastian Grosicki; Stephen Devereux; Helen McCarthy; Steven Coutre; Hang Quach; Gianluca Gaidano; Zvenyslava Maslyak; Don A Stevens; Ann Janssens; Fritz Offner; Jiří Mayer; Michael O'Dwyer; Andrzej Hellmann; Anna Schuh; Tanya Siddiqi; Aaron Polliack; Constantine S Tam; Deepali Suri; Mei Cheng; Fong Clow; Lori Styles; Danelle F James; Thomas J Kipps
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

6.  Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

Authors:  Meletios A Dimopoulos; Judith Trotman; Alessandra Tedeschi; Jeffrey V Matous; David Macdonald; Constantine Tam; Olivier Tournilhac; Shuo Ma; Albert Oriol; Leonard T Heffner; Chaim Shustik; Ramón García-Sanz; Robert F Cornell; Carlos Fernández de Larrea; Jorge J Castillo; Miquel Granell; Marie-Christine Kyrtsonis; Veronique Leblond; Argiris Symeonidis; Efstathios Kastritis; Priyanka Singh; Jianling Li; Thorsten Graef; Elizabeth Bilotti; Steven Treon; Christian Buske
Journal:  Lancet Oncol       Date:  2016-12-10       Impact factor: 41.316

Review 7.  How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.

Authors:  Samantha M Jaglowski; Bruce R Blazar
Journal:  Blood Adv       Date:  2018-08-14

8.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

Review 9.  Bruton's Tyrosine Kinase: An Emerging Key Player in Innate Immunity.

Authors:  Alexander N R Weber; Zsofia Bittner; Xiao Liu; Truong-Minh Dang; Markus Philipp Radsak; Cornelia Brunner
Journal:  Front Immunol       Date:  2017-11-08       Impact factor: 7.561
  9 in total
  1 in total

1.  Putative invasive pulmonary aspergillosis within medical wards and intensive care units: a 4-year retrospective, observational, single-centre study.

Authors:  Silvia Corcione; Tommaso Lupia; Stefania Raviolo; Giorgia Montrucchio; Alice Trentalange; Antonio Curtoni; Rossana Cavallo; Francesco Giuseppe De Rosa
Journal:  Intern Emerg Med       Date:  2021-03-22       Impact factor: 3.397
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.